Hukumar Kayayyakin Lafiya ta Ƙasa ta China ta ba wa Eporitamab fifiko kan amfani da shi ga manya marasa lafiya da suka sake kamuwa da cutar lymphoma ta follicular da ke da alaƙa da cutar.

Agusta21,Cibiyar Nazarin Magunguna (CDE) ta Hukumar Kula da Kayayyakin Lafiya ta Ƙasa (NMPA) ta ba wa mai yin amfani da ƙwayoyin T bispecific, epcoritamab, damar yin bita na musamman. An yi hakan ne ga manya marasa lafiya da ke fama da cutar lymphoma follicular da ta sake dawowa ko kuma ta sake yin illa ga ƙwayoyin B, wani yanki mai matuƙar buƙatar cutar.

A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Shaidar WeChat: 17801183037

Email：myimmnet@163.com

Game da Epcoritamab
Epcoritamab wani maganin rigakafi ne na IgG1 wanda aka ƙirƙira ta amfani da fasahar DuoBody ta Genmab kuma ana ba shi ta ƙarƙashin fata. An tsara fasahar DuoBody-CD3 ta Genmab don jagorantar ƙwayoyin T masu guba ta hanyar zaɓi don haifar da martanin rigakafi ga nau'ikan ƙwayoyin da aka nufa. An tsara Epcoritamab don ɗaurewa a lokaci guda zuwa CD3 akan ƙwayoyin T da CD20 akan ƙwayoyin B kuma yana haifar da kashe ƙwayoyin CD20+ ta hanyar ƙwayoyin T.

Game da Follicular Lymphoma (FL)
FL yawanci nau'in lymphoma wanda ba Hodgkin's lymphoma (NHL) ba ne mai wahala (ko kuma mai saurin girma) wanda ke tasowa daga ƙwayoyin B-lymphocytes kuma shine nau'i na biyu mafi yawan NHL wanda ke lissafin kashi 20-30 cikin ɗari na dukkan lamuran. Kimanin mutane 15,000 suna kamuwa da FL kowace shekara a cikin USii kuma ana ɗaukarsa ba zai iya warkewa ba tare da tsarin kulawa na yanzu.iii Marasa lafiya sau da yawa suna sake dawowa kuma, tare da kowace sake dawowa, gafara da lokacin zuwa magani na gaba yana raguwa.iv A tsawon lokaci, canzawa zuwa babban ƙwayar B-cell lymphoma (DLBCL), wani nau'in NHL mai ƙarfi wanda ke da alaƙa da mummunan sakamakon rayuwa, na iya faruwa a cikin fiye da kashi 25 cikin ɗari na marasa lafiya na FL.

EPCORE FL-1 (NCT05409066) wani gwaji ne na gwaji na mataki na 3 wanda aka buɗe don tantance aminci da ingancin epcoritamab da rituximab da lenalidomide (R2) idan aka kwatanta da R2 kaɗai a cikin marasa lafiya da ke fama da cutar sankarar mahaifa (R/R) (FL).

7 ga Agusta,Genmab A/Sya sanar da sakamako mai kyau na gwajin EPCORE FL-1 na Mataki na 3 wanda ke kimanta epcoritamab na subcutaneous, wani maganin rigakafi na bispecific, tare da rituximab da lenalidomide (R®2) idan aka kwatanta da R2 kawai don maganin manya marasa lafiya da suka sake komawa ko suka yi rashin lafiya (R/R) follicular lymphoma (FL). Binciken ya cika manyan maki biyu na jimlar amsawar (ORR, p-value < 0.0001) da rayuwa ba tare da ci gaba ba (PFS, HR 0.21, p-value < 0.0001), yana nuna bambance-bambance masu mahimmanci da mahimmanci a asibiti a duka maki biyu, yana rage haɗarin ci gaban cuta ko mutuwa da kashi 79%.

A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Shaidar WeChat: 17801183037

Email：myimmnet@163.com